People channel feed – Endpoints News

People channel feed

Ex-Tmunity chief Oz Azam lands at cancer biotech after brief detour in neurosciences

3 years ago

Acelyrin sets out for a 2021-sized IPO for California biotech’s PhIII drug

3 years ago

Seeker Biologics, a 5AM Ventures biotech led by ex-Translate Bio president, shuts down

3 years ago

Research startup Care Access lays off half of staff following Pfizer Lyme trial woes

3 years ago

Zevra CEO and two others lose board re-election as small shareholder prevails with his nominees

3 years ago

Giovanni Caforio to step down as Bristol Myers CEO, with Chris Boerner named successor

3 years ago

After a patient death in NKT trial, Athenex hires chief restructuring officer

3 years ago

Evelo again misses primary goal in atopic dermatitis and will shutter study, lay off more staff

3 years ago

Aurinia shareholder calls for sale talks, nixes support for CEO and chair

3 years ago

Lilly, Novo Nordisk, Sanofi CEOs to face off with Bernie Sanders' health committee in May

3 years ago

Ocuphire CEO says her post was terminated with no cause given

3 years ago

KBI Biopharma and Selexis hire J.D. Mowery as new CEO

3 years ago

Biden's long-awaited NIH pick might be NCI chief Monica Bertagnolli — reports

3 years ago

Trade union calls for walkouts at GSK manufacturing sites in the UK

3 years ago

Four senior FDA leaders forged close ties with Biogen well ahead of Aduhelm's approval. Now they've left FDA

3 years ago

Roche's Foundation Medicine lays off 135 workers

3 years ago

Palleon unveils PhI look at 'lawn mower' approach to glycoimmunology: #AACR23

3 years ago

#trekfortomorrow: Early lessons from the trail

3 years ago

Regeneron chairman Roy Vagelos will retire, and Len Schleifer and George Yancopoulos will co-lead the board

3 years ago

In response to ouster, fired Cutera execs sue medtech company, hit back at board members

3 years ago

Aeglea BioTherapeutics to reduce headcount to 10, seek strategic alternatives

3 years ago

Amid drama, Cutera tosses out CEO and chair, appoints replacements

3 years ago

After setting up poison pill, Quince Therapeutics board gives flat-out rejection to unsolicited buyer

3 years ago

In a bittersweet transition, Doug Williams takes on his next big biotech challenge

3 years ago

First page Previous page 27 28 293031 32 33 Next page Last page